Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
97%
Protein Tyrosine Kinase Inhibitor
59%
Overall Survival
52%
Lung Cancer
46%
Chemotherapy
44%
Erlotinib
40%
Brain Metastasis
32%
Osimertinib
31%
Immunotherapy
29%
Randomized Controlled Trial
23%
Gefitinib
21%
Survival Rate
19%
Neoplasm
19%
Cohort Study
19%
Progression Free Survival
17%
Afatinib
13%
Cisplatin
11%
Monotherapy
10%
Cancer Registry
9%
Carboplatin
7%
Epidermal Growth Factor Receptor Kinase Inhibitor
7%
Pemetrexed
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
77%
Epidermal Growth Factor Receptor
32%
Immunotherapy
32%
Overall Survival
31%
Osimertinib
27%
Lung Cancer
27%
Quality of Life
27%
Brain Metastasis
26%
Exon
19%
Survival Rate
19%
Neoplasm
19%
Tyrosine-Kinase Inhibitor
19%
Erlotinib
15%
Gefitinib
15%
EGFR Inhibitors
12%
Non-Small Cell Lung Cancer
12%
Targeted Therapy
12%
Progression Free Survival
10%
Afatinib
8%
Hazard Ratio
7%
Supportive Care
7%
Cisplatin
7%
Carboplatin
7%
Systematic Review
6%
Metastatic Carcinoma
6%
Long Term Survival
6%
Bone Metastasis
6%
Keyphrases
Epidermal Growth Factor Receptor
38%
Non-small Cell Lung Cancer (NSCLC)
38%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Tyrosine Kinase Inhibitor Treatment
20%
First-best
19%
Real-world Observational Study
19%
Copy number Gain
19%
Performance Status 2
19%
Clinical Value
19%
First-line Therapy
19%
Site-directed mutation
19%
Metagenomic Next-generation Sequencing (mNGS)
19%
Mutation Status
19%
Amplicon-based
19%
Tyrosine Kinase Inhibitor
16%
Overall Survival
12%
Doublet Therapy
10%
Cancer Inpatients
9%
Cochrane Review
9%
Confidence Interval
9%
Brain Metastases
8%
Gefitinib
8%
Erlotinib
8%
Exon 19 mutation
6%
Dual Immunotherapy
6%
Asian Population
5%
Median Overall Survival
5%
Afatinib
5%
Real-life Cohort
5%
Adjusted Hazard Ratio
5%
